Taiwan
· Delayed Price · Currency is TWD Pharmosa Biopharm Statistics
Total Valuation
Pharmosa Biopharm has a market cap or net worth of TWD 8.18 billion. The enterprise value is 6.56 billion.
| Market Cap | 8.18B |
| Enterprise Value | 6.56B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmosa Biopharm has 129.02 million shares outstanding. The number of shares has increased by 14.02% in one year.
| Shares Outstanding | 129.02M |
| Shares Change (YoY) | +14.02% |
| Shares Change (QoQ) | +8.86% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.87% |
| Float | 119.67M |
Valuation Ratios
The trailing PE ratio is 276.61.
| PE Ratio | 276.61 |
| Forward PE | n/a |
| PS Ratio | 23.40 |
| PB Ratio | 4.11 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 299.91, with an EV/FCF ratio of -70.16.
| EV / Earnings | 236.05 |
| EV / Sales | 20.23 |
| EV / EBITDA | 299.91 |
| EV / EBIT | n/a |
| EV / FCF | -70.16 |
Financial Position
The company has a current ratio of 16.29, with a Debt / Equity ratio of 6.34.
| Current Ratio | 16.29 |
| Quick Ratio | 15.76 |
| Debt / Equity | 6.34 |
| Debt / EBITDA | 7.46 |
| Debt / FCF | -1.35 |
| Interest Coverage | -2.83 |
Financial Efficiency
Return on equity (ROE) is 2.11% and return on invested capital (ROIC) is -0.43%.
| Return on Equity (ROE) | 2.11% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -0.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.31% in the last 52 weeks. The beta is 0.52, so Pharmosa Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -31.31% |
| 50-Day Moving Average | 60.83 |
| 200-Day Moving Average | 78.89 |
| Relative Strength Index (RSI) | 53.10 |
| Average Volume (20 Days) | 405,202 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmosa Biopharm had revenue of TWD 324.12 million and earned 27.78 million in profits. Earnings per share was 0.23.
| Revenue | 324.12M |
| Gross Profit | 317.23M |
| Operating Income | -9.85M |
| Pretax Income | 27.78M |
| Net Income | 27.78M |
| EBITDA | -566,000 |
| EBIT | -9.85M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
The company has 1.75 billion in cash and 126.37 million in debt, giving a net cash position of 1.62 billion or 12.58 per share.
| Cash & Cash Equivalents | 1.75B |
| Total Debt | 126.37M |
| Net Cash | 1.62B |
| Net Cash Per Share | 12.58 |
| Equity (Book Value) | 1.99B |
| Book Value Per Share | 15.44 |
| Working Capital | 1.70B |
Cash Flow
In the last 12 months, operating cash flow was 56.74 million and capital expenditures -150.19 million, giving a free cash flow of -93.45 million.
| Operating Cash Flow | 56.74M |
| Capital Expenditures | -150.19M |
| Free Cash Flow | -93.45M |
| FCF Per Share | -0.72 |
Margins
Gross margin is 97.87%, with operating and profit margins of -3.04% and 8.57%.
| Gross Margin | 97.87% |
| Operating Margin | -3.04% |
| Pretax Margin | 8.57% |
| Profit Margin | 8.57% |
| EBITDA Margin | -0.17% |
| EBIT Margin | -3.04% |
| FCF Margin | -28.83% |
Dividends & Yields
Pharmosa Biopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.02% |
| Shareholder Yield | -14.02% |
| Earnings Yield | 0.36% |
| FCF Yield | -1.14% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |